Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Summary not available.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 67th Annual Health Research Conference organized by the Caribbean Public Health Agency (CARPHA), taking place from April 27-29, 2023, in the Bahamas. This conference is the largest and longest-running health research event in the Caribbean and Latin America, aimed at promoting collaboration among health scientists and policymakers.
Co-Diagnostics will showcase its infectious disease products, including the upcoming Co-Dx PCR Home™ testing platform, which is currently under FDA review and not yet available for sale. The company has actively participated in CARPHA conferences since 2016 and is well-regarded for its innovative diagnostics technologies.
Co-Diagnostics, Inc. (NASDAQ: CODX) announced its participation in the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The ECCMID is a key event in infectious diseases, attracting over 14,000 attendees and offering a hybrid format for greater accessibility. Co-Dx aims to connect with international customers for its real-time PCR products, including the upcoming Co-Dx PCR Home™ platform, which is currently under FDA review and not yet for sale. Visitors can find the company at Booth B4-04 to learn more about its innovative diagnostics technologies, which focus on nucleic acid detection and analysis.
Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its CEO, Dwight Egan, will deliver the keynote presentation on the Co-Dx PCR Home™ testing platform at the 4th Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23, 2023, in London. The company will also host a booth at the event. The Co-Dx PCR Home™ platform is currently undergoing clinical evaluations subject to FDA review and is not yet available for sale. This conference aims to bring together experts in the field of diagnostic research.
Co-Diagnostics, Inc. (NASDAQ: CODX) is set to participate in the 10th Gene Quantification Event from March 20-24, 2023, at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Scientific Advisory Board, will present on 'At-Home PCR Testing for SARS-CoV-2' on March 20 at 2:00 PM. The presentation will highlight the feasibility of the Co-Dx PCR Home™ testing platform for at-home infectious disease diagnosis. This platform is under FDA review and is not yet for sale. The event will cover various topics including SARS-CoV-2 and liquid biopsy, featuring an industrial exhibition showcasing advancements in molecular diagnostics.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported a revenue of $34.2 million for the full year 2022, significantly down from $97.9 million in 2021, primarily due to reduced demand for Logix Smart™ COVID-19 tests. The company faced an operating loss of $27.0 million, compared to an operating income of $46.1 million the previous year. Net loss totaled $14.2 million, translating to a loss of $0.45 per diluted share. Despite these challenges, Co-Diagnostics initiated clinical evaluations for its Co-Dx PCR Home™ platform, signaling a shift towards at-home diagnostics. The company also repurchased 3.9 million shares for approximately $14.2 million.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will release its fourth quarter and full year 2022 financial results on March 16, 2023, after market close. A conference call and webcast are scheduled for that day at 4:30 p.m. EDT, featuring CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Interested participants can join the call via domestic and international lines. A replay will also be available on the company's website for those unable to attend live. Co-Diagnostics specializes in molecular diagnostics and offers innovative technology for nucleic acid analysis.
Co-Diagnostics, Inc. (NASDAQ: CODX) has announced its participation in the 30th Molecular and Precision Med TRI-CON event, taking place from March 6-8, 2023, in San Diego, CA. As a Premier Sponsor, Co-Dx will deliver a Lunch Presentation on March 6 at 11:55 am, highlighting its new Co-Dx PCR Home™ platform, which is currently undergoing clinical evaluations. The company has expanded its Marketing team to prepare for the product's commercialization, pending regulatory approval. TRI-CON serves as a key networking platform for leaders in diagnostics and precision medicine, focusing on innovations in the biotech, healthtech, and medtech sectors.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the 89th Annual American Mosquito Control Association (AMCA) conference from February 28 to March 3, 2023, in Reno, Nevada. The event is a key networking opportunity for professionals in mosquito control, where Co-Diagnostics will showcase its vector control PCR products. After a year of growth in laboratory installations and reagent purchases, the Company aims to enhance its market presence. Attendees can visit Booth #107 to learn more about Co-Diagnostics' offerings, including its Vector Smart™ tests. For more details about the conference, visit the AMCA website.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the start of clinical evaluations for its at-home and point-of-care Co-Dx PCR Home™ platform, including an initial COVID-19 test. These evaluations aim to support submissions for regulatory approvals from the FDA and other bodies. The platform utilizes patented Co-Primer™ technology, offering advanced diagnostics for infectious diseases. No specific timeline for completion has been provided due to required patient enrollment. CEO Dwight Egan emphasized the significance of this milestone, highlighting over two years of R&D and the potential global impact of this innovative diagnostic technology.